Personalisinc

Precision Genomics for Immuno-OncologyDNA Sequencing | RNA Sequencing | NGS | Immuno-Oncology | Neoantigen Prediction | Tumor Mutational Burden | Tumor Escape | Personalized Cancer Vaccine | Transcriptome | ExomePersonalis is a genomic sequencing services provider with a patented ACE (Accuracy & Content Enhanced) technology that augments coverage in difficult-to-sequence regions of the genome, such as areas of high-GC content. This ACE Platform yields the most accurate and comprehensive genetic data for pharmaceutical, biotech, clinical, and academic researchers -- providing the most reliable variant identification solution for multiple downstream applications such as:• Immuno-Oncology o Accurate detection of true somatic variants o Evaluation of tumors' mutational burden o Identification of neoantigens o Assessment of expression of immune checkpoint genes• Targeted Therapy o Extended DNA & RNA Panels o Tumor/normal or tumor only analysis mode• Clinical Diagnostics o ACE CancerPlus Test: Comprehensive tumor profiling test o ACE Clinical Exome Test: Industry-leading diagnostic yield o CLIA-licensed and CAP-accredited laboratoryLearn more at our website:

Legal name: Personalis